Background and Aim: Toll-like receptors (TLRs) modulate T cell responses in diverse diseases. Co-stimulation of T cell activation via TLR9 induces production of interferon gamma (IFN-γ), priming of which is critical for differentiation of proinflammatory macrophages. These macrophages have a crucial role in nonalcoholic fatty liver disease (NAFLD). We aimed to evaluate the expression of TLR9 protein on T cells and the consequences of TLR9-mediated triggering of these cells in patients with NAFLD. Methods: Our study included 34 patients with simple steatosis, 34 patients with nonalcoholic steatohepatitis, eight patients with NAFLD who met general diagnostic criteria but lacked histological diagnosis, and 51 control subjects. We used a synthetic TLR9 ligand to co-stimulate T cells. We measured TLR9 expression in liver and peripheral T cells and CD69 and IFN-γ as phenotypic markers of T cell activation and differentiation by flow cytometry. Results: TLR9 expression on liver and peripheral T cells was lowest in patients with simple steatosis and was positively associated with anthropometric, biochemical, and histopathological features of NAFLD. In vitro co-stimulation of T cells from patients with simple steatosis induced a limited number of IFN-γ-producing CD8 + T cells. At baseline, these patients showed a low frequency of circulating type 1 CD8 + cells. 
INTRODUCTION
Nonalcoholic fatty liver diseases (NAFLD) are a spectrum of liver diseases including simple steatosis (SS) and steatohepatitis as its more progressive form. 1 The hallmark of nonalcoholic steatohepatitis (NASH) is the intrahepatic recruitment of inflammatory cells. All cells able to produce interferon gamma (IFN-γ) in inflammation can regulate the polarization of macrophages towards a pro-inflammatory phenotype. Compared with NASH, SS patients exhibit higher numbers of intrahepatic macrophages of anti-inflammatory nature. 2 Toll-like receptors (TLR) are a family of pattern recognition receptors able to activate the innate immune system.
3 TLR9-mediated triggering of hepatic Kupffer cells is critically involved in NASH development 4 firstly because NAFLD-associated small intestinal bacterial overgrowth 2, 3 promotes the entry of TLR9 ligands of bacterial origin into the liver 5 and secondly, due to the presence of microparticles of hepatocyte origin carrying mitochondrial DNA which also functions as TLR9 ligands. 6 T cell responses in diseases of diverse etiology are modulated by TLRs expression, [7] [8] [9] [10] [11] including TLR9. 7, 8 T cells co-stimulation via T cell receptor and TLR9 causes T cell activation and IFN-γ production. 12 We have previously identified the alteration of different T cell subsets in NASH patients 13 and other authors confirmed a key role for T cells in NASH. 14 A low intrahepatic expression of TLR9 mRNA was reported in SS. 15 though it may probably come from the liver parenchyma than from T cells. So far, no study has evaluated TLR9 protein expression on T cells and the consequences of TLR9-mediated triggering in NAFLD. We hypothesized that T cells from patients with SS have a decreased expression of TLR9 and a limited production of IFN-γ.
MATERIALS AND METHODS

Patients and general procedures
Patients with NAFLD come from different centers of Buenos Aires whereas samples processing was entirely performed at the Clinical Hospital "José de San Martín". NAFLD patients group 1 comprised 68 individuals with biopsy-proven diagnosis of SS (n=34) or NASH (n=34). Its diagnosis was based on a daily alcohol consumption <20 g (females) or 30 g (males), absence of other causes of liver disease and abdominal ultrasound. 16 The histological diagnosis was based on the NAFLD Activity Score 17 and fibrosis staging 18 with score values ≥5 as the cut-off for NASH.
Liver biopsies and concomitant blood samples were used to evaluate TLR9 protein expression. NAFLD patients from group 2 were eight individuals who met the general criteria for NAFLD diagnosis but lacked histological diagnosis, hereafter called "NAFLD patients", used to evaluate TLR9 mRNA expression. Control group 1 included 11 metabolically healthy individuals who underwent antireflux surgery or cholecystectomy and did not have fatty liver which was confirmed by biopsy. Their biopsy samples were used to evaluate TLR9 protein expression. Control group 2 included 40 individuals recruited among the staff members of the Institute of Immunology, Genetics and Metabolism. All of the control individuals were given information of the study and those who intended to participate gave their written informed consent. Patients in the control groups did not received any medications within 6 months before the study, had low daily alcohol consumption, a body mass index (BMI) <25 kg/m 2 and a waist circumference <80 cm (females) or 94 cm (males). Their blood samples were used in different experiments as indicated. The BMI and waist circumference were evaluated according to the World Health Organization criteria. 19 Homeostasis Assessment Model for insulin resistance was calculated as glucose (mg/dL) × insulin (µU/mL) / 405 and measures were performed using commercial kits. Plasma levels of total cholesterol and triglycerides, aspartate and alanine aminotransferases were determined in a Cobas C-501 autoanalyzer (Roche Diagnostics, Mannheim, Germany). As transaminases normal levels slightly vary depending on the individual laboratory´s reference values, data were normalized before use. The experimental protocols and sample studies were approved by the local Ethics Committee (Clinic Hospital Ethics Committee, "Immunopathogenic factors that determine the progression of diseases as- 
Reagents
We used Ficoll-Hypaque (Pharmacia Biotech, Uppsala, Sweden), TRIZOL® reagent and Roswell Park Memorial Institute 1640 medium (Life Technologies, Gaithersburg, MD, USA) and gentamicin, glutamine, ionomycin, fetal bovine serum, phorbol 12-myristate 13-acetate and brefeldin A (Sigma Chemical Co, Saint Louis, MO, USA). Phorbol 12-myristate 13-acetate was prepared in dimethyl sulfoxide at 25 µg/mL. We used BD™ IMag anti-human CD3 magnetic particles, PermWash™, Cytofix/Cytoperm, anti-human CD3 monoclonal antibody (UCHT1) for cell stimulation, anti-TLR9-phycoerythrin (PE) (eB72-1665) and anti-CD4-Peridinin-Chlorophyll-protein (PerCP) (SK3) from Becton-Dickinson (San Diego, CA, USA), anti-CD8-Fluorescein isothiocyanate (FITC) (UCHT-4), anti-CD69-PE (FN50) and anti-IFN-γ-PE (B27) from ImmunoTools GmbH (Friesoythe, Germany). The synthetic cytidine-phosphateguanosine oligodeoxynucleotide (CpG-ODN) 2395 5'-tcgtcgttttcggcgcgcgccg-3' (Thermo Fisher Scientific, Waltham, MA, USA) used as TLR9 agonist was solubilized in sterile endotoxin-free water at 100 µM and stored at 20X until use.
Cell isolation
Peripheral blood mononuclear cells were obtained using FicollHypaque gradients and resuspended in Roswell Park Memorial Institute 1640 medium 10% fetal bovine serum, 2 mmol/L L-glutamine, and 50 µg/mL gentamicin. Twice-enriched fractions of CD3 + T cells were isolated from peripheral blood mononuclear cells (PBMC) by negative selection using magnetic particles. Recovered cells were at least 98% CD3 + . We handled liver tissues at 4ºC using a hands-on homogenization method, washed liver cell suspensions twice in phosphate buffered saline and harvested cells by centrifugation. 
Quantitative polymerase chain reaction
Intracytoplasmic IFN-γ staining
To evaluate the frequency of IFN-γ + cells at baseline, peripheral blood mononuclear cells were stimulated with 25 ng/mL phorbol 12-myristate 13-acetate and 1 mM Ionomycin in the presence of https://doi.org/10.3350/cmh.2019.0074
1 mM Brefeldin A at 37°C for 4 hours. After stimulation, cell surface staining using anti-CD4-PerCP and anti-CD8-FITC monoclonal antibodies was performed as described above, and intracytoplasmic detection of IFN-γ was done as described for TLR9. Lymphocytes were gated on a forward versus size scatter plot, the lymphoid region was further gated based on CD4 or CD8 expression, and IFN-γ expression was measured in the selected populations. To evaluate the frequency of IFN-γ + cells after co-stimulation, isolated PBMC were divided into 5×10 5 cells per well each containing 500 µL of Roswell Park Memorial Institute medium and stimulated at 37ºC for 18 hours in the presence of 1 mM Brefeldin A with 250 ng/mL soluble anti-CD3 alone or anti-CD3+2 uM CpG-ODN in 24-well culture plates. A frequency index for IFN-γ + cells was calculated as described for CD69.
Statistical analysis.
We used GraphPad Prism software (GraphPad, San Diego, CA, USA). We performed the two-tailed Mann-Whitney U test (two groups), the Kruskal-Wallis with Dunn's multiple comparison test (three or more groups), and Wilcoxon paired test (intragroup comparisons). Data were summarized using the median, first and third interquartiles and minimum and maximum values. We used the Spearman's rank correlation analysis to measure the statistical relations between TLR9 expression and continuous variables. P<0.05 was accepted as a significant value.
RESULTS
Characteristics of patients with NAFLD and control subjects
Anthropometric measurements, blood analysis and ultrasonography examination were performed at the beginning of the study (Table 1 ). All patients showed overweight or obesity and altered values of waist circumference and homeostasis assessment model for insulin resistance. We observed higher levels of aspartate and alanine aminotransferases in NASH than in SS patients from group 1. Anthropometric and biochemical values from control subjects fell into the reference ranges indicated (not shown). We described a direct relationship between plasma triglycerides concentration and fat content in NAFLD patients after comparing triglyceride levels between patients with steatosis scores "≤1" and "≥2" 
Relationship between TLR9 expression, histological and clinic-pathological features of NAFLD
We assessed TLR9 protein expression in liver cell suspensions (Fig. 1A, B Table 2 . Our results showed a positive association between TLR9 expression in CD4 + cells and liver damage. Then, we assessed TLR9 protein expression in peripheral blood mononuclear cells from the individuals previously evaluated (Fig. 1C, D) . SS patients showed the lowest TLR9 expression within CD4 + (P=0.0219) and CD8 + (P=0.0022) cell compartments (Fig. 1D) . A quantitative polymerase chain reaction-based analysis of TLR9 mRNA in CD3 + T cells confirmed a decreased expression of TLR9 mRNA in about 50% of patients (not shown). To assess the relationship between TLR9 expression at peripheral blood and clinic-pathological variables relevant to NAFLD, we performed a correlation analysis (Table 3) . NAFLD patients with a lower alteration of BMI and aminotransferases activity exhibited a lower TLR9 expression within both cell compartments. We also found a positive association between plasma triglycerides concentration and TLR9 expression in peripheral CD8 + cells. 
Synergistic interaction between signals coming from T cell receptor and TLR9 in circulating T cells
Given that a dysfunctionality of Kupffer cells in NASH 21 might enhance the influx of TLR9 ligands into the systemic circulation and interact with T cells, we explored the consequences of TLR9-mediated signaling of circulating T cells. Because cell activation is a prerequisite for T cell differentiation, we assessed CD69 upregulation and IFN-γ production as phenotypic markers of these processes. We employed isolated CD3 + cells for the assessment of cell activation to avoid the indirect effects of non-T cells, 22 and the higher affinity of non-T cells for TLR9 ligands 23 (Fig. 2) CpG-ODN treatment vs. medium, not shown). We employed peripheral blood mononuclear cells for cell differentiation assessment as a representative cellular platform that would allow the association of these results with the frequencies of IFN-γ + -producing cells at baseline (Fig. 3) . Again, anti-CD3+CpG-ODN only provided co-stimulation for IFN-γ production to CD8 + cells (intragroup comparisons: anti-CD3+CpG-ODN vs. anti-CD3 alone, not shown). Up-regulation of IFN-γ + cells was lowest in SS patients (P<0.05 vs. controls, P<0.01 vs. NASH patients). As for CD69, the addition of CpG-ODN did not alter intracellular IFN-γ production. Thus, our results demonstrated that T cells co-stimulation promoted the lowest activation and differentiation of circulating CD8 + cells in SS patients. The small size of our liver biopsies precluded its use for functional studies.
Frequency of IFN-γ + cells at baseline
We measured the frequency of circulating IFN-γ + T cells (Fig. 4) . The regulation of the inflammatory response in peripheral blood mononuclear cells is dependent on the metabolic status. 26 Since metabolic alterations associated with NAFLD are similar among our patients, the decreased expression of TLR9 on T cells from SS patients may be independent from the metabolic context, particularly from insulin even though it down modulates the expression of TLRs on T cells. 27 We showed an overall downregulation of TLR9 on T cells from SS patients affecting intrahepatic CD4 + T cells as well as peripheral CD4 + and CD8 + T cells. It can be interpreted that this feature was likely a protection adaptation from hepatocellular injury whereas the observed unvarying expression in patients with NASH may be a failure of this regulatory mechanism. The cytoplasmic tails of all TLRs contain a Toll-interleukin 1 receptor (TIR) domain. The TIR domain of TLR9 provides a binding site for an ubiquitin-protein ligase regulating its abundance and activity. 28 Since ubiquitination of proteins mediates liver protection of patients with NAFLD, 29 an increased ubiquitination of TLR9 might be involved in TLR9 downregulation on T cells from SS patients. Our study confirms previous data concerning a synergism between T cell receptors and TLR9 during the induction of IFN-γ. 12 Furthermore, it reveals a milder response in CD8 + cells from SS patients following its co-stimulation. Precise mechanistic insight exists to priming effects of IFN-γ on macrophage activation towards an inflammatory phenotype. 30 We can speculate that if the consequences of the co-stimulation were similar for intrahepatic and peripheral T cells, the decreased intrahepatic TLR9 expression observed in SS patients would promote a low number of type 1 CD8 + cells, favor the differentiation of anti-inflammatory Kupffer cells and protect against liver injury. In NASH, a failure of this regulatory mechanism would allow the progression of liver injury. As compared with controls, NASH patients showed similar TLR9 expression and similar responses after TLR9 ligation of T cells. However, NASH patients showed a higher frequency of IFN-γ-producing cells than SS patients and controls at baseline. In the context of NASH, the presence of strong pro-inflammatory adipokines and cytokines promoting type 1 CD8 + cells differentiation 31 supports these findings. The enrollment of patients in several centers from the specific area of Buenos Aires enhanced the possibility of generalizing our results to similar patients in similar settings. However, a limitation of our study was that a biopsy-proven diagnostic of NAFLD was unavailable from one of the participating centers. As we did not have an appropriate pilot study to estimate the sample size, we used information from previous studies in the same population, which allowed us to identify differences between groups provided that those differences genuinely existed in the population. 13, 32 A decreased expression of TLR9 and a limited production of IFN-γ by T cells from SS patients could play a protective role. T cells from NASH patients lack this mechanism and, furthermore, maybe influenced by strong pro-inflammatory signals of the microenvironment supporting the observed overproduction of IFN-γ. The impact of TLR9-mediated triggering of T cells within regulatory circuits potentially involved in NAFLD deserves further investigation.
